These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 33722197

  • 1. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
    Haroon S, Subramanian A, Cooper J, Anand A, Gokhale K, Byne N, Dhalla S, Acosta-Mena D, Taverner T, Okoth K, Wang J, Chandan JS, Sainsbury C, Zemedikun DT, Thomas GN, Parekh D, Marshall T, Sapey E, Adderley NJ, Nirantharakumar K.
    BMC Infect Dis; 2021 Mar 15; 21(1):262. PubMed ID: 33722197
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, Penso L, Herlemont P, Sbidian E, Weill A, Dray-Spira R, Zureik M.
    Hypertension; 2021 Mar 03; 77(3):833-842. PubMed ID: 33423528
    [Abstract] [Full Text] [Related]

  • 3. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G, Massari M, Da Cas R, Menniti Ippolito F, Sultana J, Crisafulli S, Giorgi Rossi P, Marino M, Zorzi M, Bovo E, Leoni O, Ludergnani M, Spila Alegiani S, ITA-COVID-19: RAAS inhibitor group.
    Drug Saf; 2020 Dec 03; 43(12):1297-1308. PubMed ID: 32852721
    [Abstract] [Full Text] [Related]

  • 4. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
    Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer SB, Vojta D, Krumholz HM.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e018086. PubMed ID: 33624516
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy.
    Wen X, Otoo MN, Tang J, Brothers T, Ward KE, Asal N, Meador KJ.
    JAMA Neurol; 2024 Aug 01; 81(8):866-874. PubMed ID: 38884986
    [Abstract] [Full Text] [Related]

  • 6. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
    Bezabih YM, Bezabih A, Alamneh E, Peterson GM, Bezabhe W.
    BMC Infect Dis; 2021 Jun 05; 21(1):527. PubMed ID: 34090358
    [Abstract] [Full Text] [Related]

  • 7. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
    Kim J, Kim DW, Kim KI, Kim HB, Kim JH, Lee YG, Byeon KH, Cheong HK, Korean Society of Hypertension.
    J Korean Med Sci; 2020 Jun 29; 35(25):e232. PubMed ID: 32597045
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J, Jo SJ, Cho Y, Lee JH, Oh IY, Park JJ, Cho YS, Choi DJ.
    Korean J Intern Med; 2021 Mar 29; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [Abstract] [Full Text] [Related]

  • 9. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJ.
    Am J Kidney Dis; 2021 May 29; 77(5):719-729.e1. PubMed ID: 33246024
    [Abstract] [Full Text] [Related]

  • 10. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
    Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, Hospital-Guardiola I, de Diego-Cabanes C, Bejarano-Romero F, Rovira-Veciana D, Basora-Gallisa J.
    J Clin Hypertens (Greenwich); 2020 Aug 29; 22(8):1379-1388. PubMed ID: 32710674
    [Abstract] [Full Text] [Related]

  • 11. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
    Kwok T, Leung J, Barrett-Connor E, Osteoporotic Fractures in Men (MrOS) Research Group.
    Age Ageing; 2017 Jan 10; 46(1):57-64. PubMed ID: 28181652
    [Abstract] [Full Text] [Related]

  • 12. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, Vassiliou VS.
    JAMA Netw Open; 2021 Mar 01; 4(3):e213594. PubMed ID: 33787911
    [Abstract] [Full Text] [Related]

  • 13. Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.
    Hsiao FC, Tung YC, Chou SH, Wu LS, Lin CP, Wang CL, Lin YS, Chang CJ, Chu PH.
    Medicine (Baltimore); 2015 Dec 01; 94(51):e2355. PubMed ID: 26705234
    [Abstract] [Full Text] [Related]

  • 14. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z, Zhang D, Wang S, Jin Y, Huan J, Wu Y, Xia C, Li Z, Qi X, Zhang D, Han X, Zhu X, Qu Y, Wang Q.
    Med Sci Monit; 2020 Sep 24; 26():e926651. PubMed ID: 32969367
    [Abstract] [Full Text] [Related]

  • 15. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration.
    Vascul Pharmacol; 2020 Dec 24; 135():106805. PubMed ID: 32992048
    [Abstract] [Full Text] [Related]

  • 16. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
    Lee HY, Ahn J, Park J, Kang CK, Won SH, Kim DW, Park JH, Chung KH, Joh JS, Bang JH, Kang CH, Oh MD, Pyun WB, Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases.
    Korean J Intern Med; 2021 May 24; 36(3):617-628. PubMed ID: 33858123
    [Abstract] [Full Text] [Related]

  • 17. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.
    Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154
    [Abstract] [Full Text] [Related]

  • 18. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
    Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, McDonald A, Arruda P, Kriebel D.
    J Clin Hypertens (Greenwich); 2021 Jan 11; 23(1):21-27. PubMed ID: 33220171
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
    Liu X, Liu Y, Chen K, Yan S, Bai X, Li J, Liu D.
    J Med Virol; 2021 Feb 11; 93(2):854-862. PubMed ID: 32687223
    [Abstract] [Full Text] [Related]

  • 20. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
    Safizadeh F, Nguyen TNM, Brenner H, Schöttker B.
    Br J Clin Pharmacol; 2022 Jun 11; 88(6):2830-2842. PubMed ID: 34935181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.